SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CLDX Celldex Therapeudics
An SI Board Since September 2016
Posts SubjectMarks Bans Symbol
55 10 0 CLDX
Emcee:  Michael L Type:  Moderated
Welcome to a new Celldex board. Former Yahoo board members feel free to introduce yourself.

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
55just parking, nothing to see here....... Cell Signal. 2020 Jan 3:109525. doi: 1scaram(o)uche-January 12
54tandfonline.com >> The first agonistic antibody to enter the clinic was dscaram(o)uche-January 12
53Re. CDX-1140..... wouldn't it be great if it (getting T cells into solid cscaram(o)uche-12/31/2019
52Just parking. Nothing to see here. Emphasis mine. J Clin Med. 2019 Nov 7;8(11scaram(o)uche-12/22/2019
51Investigator-sponsored trial updated today, no substantial change. Anti-CD27, Gscaram(o)uche-12/17/2019
50Business development should be working to license CDX-0159 for intravitreal formscaram(o)uche-12/17/2019
49ahajournals.org <i>Our data reveal that SCF and cKIT are promising novel scaram(o)uche-12/17/2019
48Investigator-sponsored trial updated today, no substantial change. Anti-CD27, Gscaram(o)uche-12/17/2019
47Nice wrinkle re. anti-MerTK and its role in NASH fibrosis....... Cell Metab. 20scaram(o)uche-12/17/2019
46>> Studies from our laboratory and others have shown that acquired lapatinscaram(o)uche-12/15/2019
45CDX-1140 is a reduced-toxicity CD40 agonist which does not block CD40/CD40L intescaram(o)uche-12/14/2019
44Missed this one, not important for business plan, CDX-301...... Cell Rep. 2019 scaram(o)uche-12/12/2019
43Entire world going nuts about IL-2 mimetics (THOR et al.), while "toxicity-scaram(o)uche-12/9/2019
42<i>Pursuant to Rule 415(a)(6) under the Securities Act, the securities regscaram(o)uche-12/9/2019
41Mixed shelf. Maybe they're trying to make nice with a few institutions. Bescaram(o)uche-12/9/2019
40Novartis experience with moving (in this case, conjugated) anti-kit into clinic scaram(o)uche-12/9/2019
39Well, the CEO has been abusing shareholders for years. And the recent business scaram(o)uche112/3/2019
38Yep. Of the 70-ish healthcare-focused funds that I track, 22 have owned CLDX at bmaz001-12/3/2019
37>> anti-kit from the FTSV perspective << and here is the perspectivscaram(o)uche-12/2/2019
36>> the CLDX TAM program is valued at minus $30 million << ........ scaram(o)uche-12/2/2019
35One million aggregate HF 13F shares. No respect! (which is richly deserved, buscaram(o)uche-12/2/2019
34Cool, thanks! Just parking (only preclinical!), may do a bit of it......... Cascaram(o)uche-12/2/2019
33Thanks, Rick. Here's a link to my workbook with additional CLDX info. CLDXbmaz001-12/2/2019
32Here is a description of anti-kit from the FTSV perspective........... fortysevscaram(o)uche-12/2/2019
31This study has been updated and looks like it might get going....... clinicaltrscaram(o)uche-11/29/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):